Bencard Allergy Laboratories

Allergy Therapeutics, historically known as Bencard Allergy Laboratories, is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies for the treatment and diagnosis of allergies. The company focuses on allergen-specific immunotherapy (ASIT), utilizing its proprietary Pollinex Quattro platform which combines modified allergens (MATAs) with the adjuvant Monophosphoryl Lipid A (MPL) to provide short-course subcutaneous treatments. Its extensive portfolio includes products for seasonal and perennial allergies, such as Pollinex and Venomil, as well as a promising pipeline featuring a virus-like particle (VLP) based vaccine for peanut allergy. Headquartered in the UK and maintaining a strong presence in Germany through its Bencard Allergie subsidiary, the company serves a global market with a focus on improving patient compliance and treatment efficacy.